Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark. Show more

Location: Dr. Neergaards Vej, Horsholm, 2970, Denmark | Website: https://evaxion.ai | Industry: Biotechnology | Sector: Healthcare


Market Cap

16.8M

52 Wk Range

$1.20 - $17.75

Previous Close

$2.58

Open

$2.77

Volume

366,420

Day Range

$2.54 - $2.85

Enterprise Value

659.1M

Cash

17.84M

Avg Qtr Burn

N/A

Insider Ownership

23.07%

Institutional Own.

7.09%

Qtr Updated

03/31/25